Companies in #Acute Respiratory Distress Syndrome
Found 2 companies operating in this sector.
Edesa Biotech is a clinical-stage biopharmaceutical company developing host-directed therapeutics for immuno-inflammatory diseases, built around alternatives to steroids and JAK inhibitors. Its lead candidate, paridiprubart (EB05), is a first-in-class anti-TLR4 antibody that has completed late-stage study in acute respiratory distress syndrome, reporting a statistically significant reduction in adjusted 28-day mortality versus standard of care in an expanded 278-patient Phase 3 dataset; the molecule is also being studied in acute kidney injury and in a U.S. government-funded host-directed therapeutics platform study. A second program, EB06, is an anti-CXCL10 monoclonal antibody in a Phase 2 study in moderate-to-severe nonsegmental vitiligo, with site activation in Canada underway. The Nasdaq-listed entity was formed in June 2019, when the private Canadian company Edesa Biotech combined with Stellar Biotechnologies in a share exchange and began trading under the symbol EDSA; executive offices are in Markham, Ontario, in the Greater Toronto Area. The company remains pre-revenue, exited fiscal Q3 2026 with roughly $10.3 million of cash and a $5.4 million quarterly net loss, and augmented its balance sheet in August 2026 with a $25.0 million underwritten equity offering priced at $5.50 per unit.
MediciNova is a biopharmaceutical company developing small-molecule therapeutics licensed from Japanese originators for serious diseases with unmet medical need, and is dual-listed on Nasdaq and the Tokyo Stock Exchange. Its lead compound MN-166 (ibudilast) is an oral anti-inflammatory and neuroprotective agent in clinical development for amyotrophic lateral sclerosis (the Phase 2b/3 COMBAT-ALS registration trial enrolled 234 patients, with top-line data expected by year-end 2026), progressive multiple sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma and prevention of acute respiratory distress syndrome; an expanded-access program in ALS is supported by a $22 million NIH grant. The second compound, MN-001 (tipelukast), is an orally bioavailable small molecule in development for fibrotic and metabolic disorders including nonalcoholic fatty liver disease and hypertriglyceridemia. Management has framed 2026 as a data-driven year led by readouts from these two programs rather than by financing.